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This Perspective describes (a) the current situation, (b) challenges and initiatives, (c) and for-
mulates recommendations to valorize and create access to innovative medicines in the EU.
We are currently still far away from optimal assessment of value for money in the EU. On
the one hand, valorizing innovativemedicines involves a local appraisal by health technology
assessment (HTA) bodies and competent authorities about the value for money, the budget
impact, and the local medical need that can be ﬁlled with new medicines. Therefore, local
priorities and national health care policy environments should be reﬂected in the processes
and criteria used for assessing value formoney and ultimately for reimbursement decisions.
On the other hand, a pan-European assessment of both relative effectiveness and medical
need (including general ethical and social considerations) should be envisaged in order to
feed part of the data needed for the local decisions in an efﬁcient way. This could be the
task of the European Medicines Agency, HTA bodies, and competent authorities together.
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INTRODUCTION
If investing in health is considered to be an investment of human
and ﬁnancial resources with a view to attain a higher health status
for society, it is self-evident that this society should monitor the
cost–effectiveness or value for money of this investment. There-
fore, once a new medicine can be considered as truly innovative,
i.e., showing an added therapeutic value and ﬁlling a medical need,
the question is whether it is worthwhile to spend public money to
cover the cost of this medicine taking into account its therapeutic
value, i.e., is the medicine cost–effective?
Explicit decisionsmust bemade about funding a newmedicine,
mostly by third-party payers (especially social health insurance
institutions or national health services or bodies representing
them), taking into account a legitimate return on investment for
the pharmaceutical company, transparent prices, and value for
money. These decision makers are involved with allocating health
care budgets and use more and more standardized methods of sys-
tematically assessing and appraising such medicines. Criteria such
as relative effectiveness, cost–effectiveness, budget impact, med-
ical/therapeutic needs, social, and ethical considerations, play a
role in these decisions.
This Perspective describes (a) the current situation of the intro-
duction of innovative medicines in the EU, (b) the challenges
and initiatives identiﬁed, and (c) formulates recommendations
to valorize and create access to them.
CURRENT SITUATION RELATED TO VALUE FOR MONEY
ASSESSMENT OF INNOVATIVE MEDICINES
In deciding whether or not to reimburse the cost of medicinal
products, Member States must take into account the principles
laid down in Directive 89/105/EEC (European Commission,
1989). The explicit assessment of cost–effectiveness and budgetary
impact is however not mandatory at the EU level, but it is the
responsibility of the Member States to implement such criteria
or not.
Internationally, the ﬁrst countries implementing such assess-
ments were Australia and Canada in the early 1990s (O’Donnell
et al., 2009; International Society for Pharmacoeconomics and
Outcomes Research, 2011). The National Institute for Health and
Clinical Excellence (NICE) in England and Wales uses a cost–
effectiveness threshold of £20,000 per quality-adjusted life year
(QALY), although health technologies with an incremental cost–
effectiveness ratio above this threshold can be recommended for
use in the National Health Service if there is a strong case to do
so. A review of NICE guidance issued between 1999 and 2005
concluded that health technologies having an incremental cost–
effectiveness ratio exceeding £30,000 per QALY were unlikely to be
recommended (Raftery, 2006). Judgments about what is regarded
as an (un)acceptable ratio are made by NICE’s advisory commit-
tees, which consist of clinicians and health managers, statisticians,
health economists, and patients (Rawlins and Culyer, 2004).
The BelgianMedicine Reimbursement Committee does not use
a cost–effectiveness threshold when assessing the value for money
of medicines. A retrospective analysis reviewed 824 pharmaceu-
tical reimbursement dossiers that included therapeutic value and
that were submitted between 2002 and 2004. Of those dossiers,
81% gained reimbursement, whereas 19% did not. If the appli-
cant proved added therapeutic value versus available alternatives,
the probability of reimbursement increased to 91% (Van Wilder
and Dupont, 2008).
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In Ireland, new medicines with an ICER below 45,000 C per
QALY tended to be reimbursed. If a medicine has an ICER that is
signiﬁcantly higher than other technologies that have been funded
or reimbursed, other factors need to be considered, such as: the
level of uncertainty associated with the effectiveness and cost–
effectiveness data, the budget impact and the opportunity cost
of investing in the new medicine, the innovative nature of the
medicine, and the availability of alternatives (Tilson and Barry,
2010).
The Scottish Medicine Consortium has assessed the value for
money of around 600 medicines from 2002 to 2008 (Webb, 2009).
Of these 600 medicines, 30% were accepted for use, 33% were
accepted for restricted use, and 37% were not recommended. If
the cost per QALY was less than or equal to £20,000 per QALY,
there was a probability of 80% that the medicine was accepted.
If the cost per QALY ranged from £20,000 to £30,000 per QALY,
this probability decreased to 42%. A submission was more likely
to succeed if one or more of the following conditions was satisﬁed:
innovative treatment, clear effect on relevant clinical outcomes,
sizeableQALYbeneﬁt and clear cost perQALY case,direct compar-
ison with current practice, transparent modeling with sensitivity
analysis, and data relevant to Scottish patients.
A recent review compared the assessments conducted by the
NICE in the UK with those of the Australian Pharmaceutical Ben-
eﬁts Advisory Committee (PBAC) and the Canadian Agency for
Drugs and Technologies in Health’s Common Drug Review (CDR;
Clement et al., 2009). According to the authors, the three agencies
make recommendations that are consistentwith evidence on effec-
tiveness and cost–effectiveness but other factors (medical need,
ethical considerations, budget impact) are often important.
It is clear that such conclusions are also valid within the EU,
where the context, agency processes, ability to engage in price
negotiation, and social values differ among countries.
The role of health technology assessment (HTA) in the process
of pricing and reimbursement is becoming crucial, since HTA
by deﬁnition takes all the required criteria for decision making
into consideration and also looks at best practices with tech-
nologies. The HTA-methodology might therefore beneﬁt Member
States in the implementation of an objective, veriﬁable, and trans-
parent decision making process. But many challenges remain in
place.
CHALLENGES AND INITIATIVES RELATED TO VALUE FOR
MONEY ASSESSMENT AND ACCESS TO INNOVATIVE
MEDICINES
DIFFERENT STRUCTURES AND PROCESSES
The role of HTA indecisionmaking strongly differs betweenMem-
ber States. Sorenson et al. (2008) explain that divergent structures,
processes, and roles may hinder the efﬁciency of the decision mak-
ing process and lead to unnecessary duplication of efforts and
resource use.
On the structural level, some countries have different institu-
tions involved in HTA, with overlapping responsibilities and tasks
and a lack of coordinated recommendations; others have no HTA
facilities and are required to rely on foreign evaluations, which
may not always come to conclusions that are relevant to their local
situation.
On the process level, the applied methodologies are different,
limiting the comparability, and transferability across countries.
Also, lack of transparency, accountability, and stakeholder involve-
ment is often cited as a common ﬂaw of current systems. Finally,
any process should foresee that recommendations need to be
reviewed on a regular basis in order to account for the evolving
practice in any given disease area.
It is crucial that HTA bodies, national competent authori-
ties, and the European Medicines Agency (EMA) work closer
together with transparent assignment of roles and responsibilities
in order to avoid duplication of efforts on the one hand or lack
of adequate data for decision making on the other hand. The cre-
ation of the European Network for Health Technology Assessment
(EUnetHTA) has made a signiﬁcant contribution to the coordina-
tion of HTA in the EU. A dialog is currently taking place between
HTA agencies and EMA in order to align the agencies’ activities
and roles with those of the EMA and national competent author-
ities, as recommended by the High Level Pharmaceutical Forum
(European Medicines Agency, 2009).
APPLYING HTA CRITERIA
Differences in health care systems and in the organization of HTA
probably explain a large part of the variance in international HTA.
Also, differences in how HTA is perceived, understood or used in
various parts of the world may have an important impact on the
way it is performed and used.Hence, different applications of HTA
may exist even in settingswhere there are no substantial differences
in the health care system or in the organization of HTA.
With regard to the applied criteria, most HTA assessments take
a variety of criteria into consideration, including relative effective-
ness, cost–effectiveness, budget impact, and medical/therapeutic
need. Some countries also explicitly include the public health
impact and equity considerations. Some apply a societal perspec-
tive, while others apply a more restricted health care perspective.
Few countries apply a formal threshold for willingness to pay for
one unit of extra health, and even the standard unit of the QALY
is challenged by several Member States (Cleemput et al., 2008).
Collaboration on HTA between Member States requires stan-
dardization in the structure, transparency, and handling of infor-
mation in any HTA. Steps toward deﬁning some standards at
the international level have been taken by the International Net-
work of Agencies for Health Technology Assessment (INAHTA)
and previous European Projects (EUR-ASSESS, ECHTA/ECAHI).
More recently, EUnetHTA was established, as a response to the
expressed need by the European Commission and Member States
for a sustainable European Network for HTA (Kristensen et al.,
2009).
The HTA Core Model developed within the EUnetHTA project
built on this earlier work (Lampe et al., 2009). The HTA Core
Model speciﬁes the questions that should be asked and answered
within an HTA and deﬁnes and standardizes the structure of an
HTA report. To support European collaboration some elements
are prioritized over others. They are deﬁned as “core elements.”
A core element is an assessment element that is considered to be
both important for every HTA and transferable to other jurisdic-
tions. A Core HTA is an actual assessment that has been conducted
using the HTA Core Model and has considered all core elements
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of all nine HTA domains (i.e., health problem and current use of
the technology; description and technical characteristics of tech-
nology; safety; clinical effectiveness; costs, economic evaluation;
ethical analysis; organizational aspects; social aspects; and legal
aspects). Through the wide scope, focus on core elements and the
summary chapter, a Core HTA gives an overview of a technology
that is likely to be useful in the European context and that can
be used as a basis for producing local HTA reports that take into
account local circumstances.
UNCERTAINTY AND PERFORMANCE-BASED AGREEMENTS
A crucial element in value for money assessment is how to deal
with uncertainty surrounding effectiveness, costs, and budgetary
impact of medicines. A possible way to deal with this uncer-
tainty is the application of risk sharing agreements, or more
broadly “performance-based agreements” (Carlson et al., 2009).
Performance-based agreements could be deﬁned as formal agree-
ments between a health care payer and a manufacturer where
the price level and/or revenue received is related to the (future)
performance of the product in order to remain within prede-
ﬁned limits in terms of cost–effectiveness. In these agreements,
the eventual effectiveness and costs will drive formal actions ori-
ented to conditional reimbursement, such as companies having
to pay for the medicine themselves in case of treatment fail-
ure or paying back part of the reimbursed money in case of
worse than expected cost–effectiveness. The crucial requirement
for performance-based agreements to be effective is that it has to
be possible to measure performance and to make reasonably good
assessments of the value in “real life.” Measuring performance
means objectively measuring outcomes on scientiﬁcally validated
clinical endpoints as well as patient reported outcomes (PROs;
Dubois, 2010).
Performance-based agreements are in the interest of the indus-
try, since companies can beneﬁt from new information becoming
available on non-clinical positive attributes, such as compliance,
impact on quality of life, comfort for health workers, and poten-
tial cost–savings. Moreover, predictability of a “fair” list price,
reﬂecting the true value of the product, can be an incentive to
further invest in innovative research. Flexible discount and rebate
schemes can also provide means to meet the willingness to pay
of the health care payer, without touching the global price and
the impact on revenue due to benchmarking of pharmaceuti-
cal prices across several countries (“external reference pricing”).
Additionally, performance-based agreements can be a valuable
asset to Compassionate Use and Medical Need Programs to pro-
vide access to promising innovative pharmaceutical therapies in
domains where an unmet medical need is identiﬁed,without com-
promising the delicate equilibrium between cost and effectiveness,
while at the same time enhancing transparency indecisionmaking.
Over the last two decades, numerous performance-based agree-
ments have been put into place. Relative simple “No Cure, no
pay”and“MoneyBackGuarantee”-schemes have been established,
such as those for ﬁnasteride (US) in benign prostatic hyperpla-
sia, for vardenaﬁl (Denmark) in erectile dysfunction, for valsartan
(US and Denmark) in blood pressure treatment, and for borte-
zomib (UK) in multiple myeloma (National Institute for Health
and Clinical Excellence, 2007), alongside with more sophisticated
schemes as the UK Risk Sharing Scheme for Multiple Sclerosis
(price adjustment to ensure an agreed threshold value for the cost–
effectiveness ratio; Sudlow and Counsell, 2003), a US “inversed”
discount scheme (greater discount in case of greater performance)
for sitagliptin (+metformin) in type 2 diabetes and US cover-
age of disease-related sequelae in case of non-performance for
risendronate in the treatment of osteoporosis. However, concerns
have been raised about some of these schemes such as the UK Risk
Sharing Scheme for Multiple Sclerosis and some have argued that
the money should be better allocated to funding a randomized
controlled trial of the medicines involved in the scheme (Raftery,
2010).
Today such agreements often take place at the end of a some-
times long negotiation between a pharmaceutical company and
a decision maker and are considered as a kind of last resort
(European Commission, 2005). Also, early access to new phar-
maceutical technologies means early exposure, including the risks
involved in using technologies that are not fully evaluated, for
instance on long-term safety. This may cause the patient to miss
out on optimal treatment for a period of time, or worse, expose
patients to a treatment with possible adverse and harmful effects.
Other possible disadvantages occur. For establishing sophisticated
schemes, data collection and analysis, complex monitoring and
review must be feasible and will generate an extra administrative
and bureaucratic burden and additional costs for the industry,
payers, and administrators. In fact, this might even delay market
access. Prices of newmedicinesmight rise in anticipation of subse-
quent performance-based adjustments. Therapies that prove not
to be clinically or cost–effective for the whole target population
might be difﬁcult to withdraw if there is proof of beneﬁt for some
individual patients. Granting conditional reimbursement could
also jeopardize incentives for manufacturers to further invest in
additional data collection by means of optimal evaluative study
design and study conduct. Furthermore, the clinical community
may regard this experimental research to be unethical and patients
could be reluctant to participate in such schemes.
AFFORDABILITY, ACCESS, AND SOLIDARITY
Innovative medicines are generally launched in markets where
the companies can get a high price for them and then launched
in other markets later. These later markets decide the price by
looking at prices in other countries, so that there is little price
difference, which makes it difﬁcult for low-income countries to
have affordable access to medicines (Docteur and Paris, 2008). A
crucial challenge in the EU context is to make valuable innovative
medicines accessible to all EU citizens, which requires solidar-
ity within Member States and solidarity between Member States.
Ideally, valuable innovative medicines should be launched in all
markets and available there at an affordable price.
With regard to within country solidarity, it is important to
understand that cost–effectiveness estimates do not account for
distributive aspects (poor/rich; young/old; rare diseases, . . .). The
utilitarian vision on health investment goes against the principle
that everyone has the right to the same quality of health care.
Perhaps the societal willingness to pay for QALYs or the QALYs
themselves should be weighted for factors such as severity of dis-
ease. Reﬂection is needed on a country level about the elements
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based on which such solidarity and weighing can be achieved, and
all stakeholders need to be involved.A good example is given by the
citizen’s council reports in the UK (National Institute for Health
and Clinical Excellence, 2005).
But reﬂection is also needed at the EU level, related to between
Member State solidarity. In principle all Europeans have the right
to the same quality of health care and it is not acceptable that in
case of a severe condition inhabitants of country X have access
to new treatment whereas inhabitants of country Y do not. Obvi-
ously, due to differences in health systems and priorities, a solution
for this problem will be very difﬁcult to achieve.
It should perhaps be explored whether a system of price differ-
entiation canbe applied in functionof countries’GDPper capita in
order to enable such access. Although these kind of pricing systems
reﬂect in a sense the principles of solidarity and equity, as coun-
tries with more resources would carry part of the ﬁnancial burden
of more vulnerable countries, reﬂection on implementation is
needed. The establishment of a systematic price differentiation
scheme would call for the determination of some sort of Euro-
pean “base” price, reﬂecting the value and the value for money of
medicines on a European level.A European“average”price, reﬂect-
ing a European “average” value for money would not necessarily
reﬂect the true value for money for individual countries given
that health priorities can differ between vulnerable countries and
countries with more ﬁnancial power. It remains to be examined if
adjustments or price differentiation, merely on GDP, will sufﬁce,
and should they not, which other criteria could be considered.
At the same time, as these schemes could in a way be considered
as external reference pricing schemes, they could limit the scope
for individual countries to negotiate (for instance compensation
mechanisms or performance-based agreements) on prices of the
concerned pharmaceuticals.
It should also be examined how these differential pricing sys-
tems can be structured in a way that is compatible with the
European regulation on the internal market, more speciﬁcally on
free trafﬁc of goods, the freedom to provide services, and the free-
domof establishment. Free parallel import and export for instance,
should not be hampered or hinder itself the efﬁciency and sus-
tainability of such structures. As a minimum, systems should be
put in place that guarantee that those medicines offered on the
local market effectively reach local patients. A way forward could
be to consider innovative pharmaceutical medicines as a social
insurance service, hence not requiring the rules of the EU internal
market.
ADDITIONAL CHALLENGES FOR ORPHAN MEDICINES
For orphan medicines, additional challenges occur. Indeed, given
their high price for an often modest health beneﬁt, orphan med-
icines are often unlikely to be cost–effective, at least if the cost–
effectiveness of an intervention is judged based on its cost per
QALY gained, and this cost per QALY is compared to a ﬁxed
threshold value.
Possibly, additional criteria that are not included in the tradi-
tional cost per QALY measure (e.g., the seriousness of the health
condition; the availability of other therapies to treat the disease;
and the cost to the patient if the medicine is not reimbursed,
. . .) can even be more relevant to inform decisions on orphan
medicines. The question arises as to how these various consid-
erations can be aggregated. In contrast with medicines for non-
orphan diseases, how can the often poor cost–effectiveness ratio,
weak clinical data, small health beneﬁt, high cost, and absence
of an alternative therapy for orphan medicines be taken into
account in a payer’s decision to cover such a medicine? It could
be argued that the cost–effectiveness threshold value should be
higher for medicines to which society attaches a high social value.
Orphan medicines may attract a high social value, although future
research will have to elicit social values ascribed to various health
technologies.
The newly agreed EU principle that “Member States, stake-
holders, and the Commission should strengthen their efforts to
ensure access to orphan medicines in all EU Member States,” led
to the EU exchange of knowledge on the scientiﬁc assessment of
the clinical added value of orphan medicines, speciﬁc pricing and
reimbursement mechanisms and an early dialog on research and
development, as well as an increased awareness on rare/orphan
diseases (European Commission, 2005). Still it is felt that EU pol-
icy makers should share more intensively their considerations and
criteria when deciding on adopting (reimbursing) orphan med-
icines and more efforts should be made to coordinate processes
and criteria.
ADDITIONAL CHALLENGES FOR PERSONALIZED MEDICINE
A special challenge exists in the assessment of medicinal products
whose use is or can be dependent on the result of genetic tests.
Often the decision makers dealing with the value for money of
such tests are different from those dealing with medicines, and the
criteria applied are different as well, leading to additional prob-
lems of lack of coordination. The same principles of cost–effective
use and budget impact should also apply to such genetic tests, and
the decision making for tests and associated medicines must be
aligned.
RECOMMENDED WAYS FORWARD
We are currently still far away from optimal assessment of value
for money in the EU. On the one hand, valorizing innovative
medicines involves a local appraisal of the value for money, the
budget impact, and the local medical need that can be ﬁlled with
new medicines. Although unmet medical needs tend to be the
same across the EU, medical needs may differ between countries
when for example a medicine for a rare disease is reimbursed in
one country, but not in another country. Indeed, local priorities
and national health care policy environments should be reﬂected
in the processes and criteria used for assessing value for money
and ultimately for reimbursement decisions. On the other hand,
a pan-European, coordinated or even integrated assessment of
both relative effectiveness and medical need (including general
ethical and social considerations) should be envisaged in order to
feed part of the data needed for the local decisions in an efﬁcient
way. Our proposal for a Joint Initiative for Medicines could be
the task of EMA, HTA bodies, and national competent authorities
together.
Local assessment of medical need, supplementary ethical
and social aspects, cost–effectiveness, and budget impact should
then remain the responsibility of the Member States, although
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Table 1 | Assessment of innovative medicines in the European Union.
Assessment criteria for
innovative medicines
Current Future
Centralized Local Integrated Local with exchange
EMA HTA and competent
bodies
Joint initiative
for medicines
HTA bodies and
competent bodies
Efﬁcacy   
Safety   
Relative efﬁcacy   
Relative effectiveness  
EU medical need  
Local medical need   
Ethical and social aspects   
Cost–effectiveness  
Budget impact  
Organizational aspects  
The Joint Initiative for Medicines refers to our proposal for a joint initiative between EMA, HTA bodies, and national competent authorities.
cross-border exchange of methods, information, and decisions
would be highly valuable.Note that local assessmentsmay be based
on core international cost–effectiveness and budget impactmodels
that are adapted to the local setting.
According to this scheme, similar outcomes of relative effective-
ness assessments will nevertheless allow different Member States
to come to different reimbursement decisions based on either dif-
ferences in value judgment or budgetary evaluations, or on any
other reason for that matter, such as differences in the objectives
and priorities of the different national health care systems.
Future discussions between Member States should strive at
deﬁning and triggering such a dual system with an integrated
approach for relative effectiveness and EU medical need assess-
ment and a coordinated/exchange based approach for value for
money assessment. Table 1 illustrates the desired shift as compared
to the current situation.
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